Document wqMK1GrKXeoL3VGz6bzbL8vD

2261 MINUTES 5T""the three-hundredth meeting of the Board of Directors of the Chemical.Manufacturers Association, Inc., held in the West Alabama Room, The Westfn Galleria, Houston, Texas, on Tuesday, October 30, 1984, at 9:00 a.m. There were present: Directors: Edwin C. Holmer, Chairman W. H. Clark, Jr., vice Chairman Richard G. Askew Lee K. Bailey Robert H. Malott Fred W. Montanari Max S. Bass Seymour S. Preston, III Robert D. Cadieux Toy F. Reid Ralph S. Cunningham Thomas E. Reilly, Jr. Keith H. Edmondson Robert A. Roland Robert B. Fell David L. Rooke John T. Files Vincent A. Sarni Robert C. Forney George J. Sella, Jr. Ben C. Hayton Donald F. Smith Ray R. Irani Harold A. Sorgenti John W. Johnstone, Jr. Charles E. Stewart Sidney M. Leahy J. R. Street Richard J. Mahoney Otto Sturzenegger Secretary: Treasurer: General Counsel: Charles W. Van Vlack Gary C. Herrman David F. Zoll By Invitation: Peter R. Agnew, CMA Stuart T. Allen, SOCMA, E. I. du Pont de Nemours & Company David L. Baird, Jr., Exxon Chemical Company Geraldine V. Cox, CMA Louis Fernandez, Monsanto Company Paul E. Hime, Texas Chemical Council, Celanese Chemical Company Jon C. Holtzman, CMA E. Hamilton Hurst, Nalco Chemical Company Bruce W. Karrh, M.D., E. I. du Pont de Nemours & Company John Klacsmann, Clean Sites, Inc. Stacey J. Mobley, E. I. du Pont de Nemours & Company Timothy F. O'Leary, CMA Victor H. Peterson, CMA Charles W. Powers, Clean Sites, Inc. Vernon R. Rice, E. I. du Pont de Nemours & Company Randal P. Schumacher, CMA Charles T. Seay, Texas Chemical Council, Exxon Chemical Americas William M. Stover, CMA Juliane H. Van Egmond, American Cyanamid Company Harry P. Whitworth, Texas Chemical Council Albert M. Wolford, Texas Chemical Council, Texas United Chemical Corporation Part Time CMA 012655 OSHA's favor in which the Court showed considerable deference to the^Agency's 1) approach to risk assessment; 2) judgment regarding the significance of various levels of risk; and 3) determinations of technological and economic feasibility. ETHYLENE DICHLORIDE -- The Program Panel filed comments with EPA on Recommended Maximum Contaminant Levels for EDC in Drinking Water. The comments critiqued the Occurrence Document and Criteria Document on EDC, the documents that formed the basis for EPA's recommendation of zero level for EDC in drinking water. The Panel recommended that a zero level not be established for EDC in drinking water, and emphasized that the weight of the evidence does not support EPA's contention that EDC is a probable human carcinogen. KETONES -- The Ketones Program Panel completed all testing under the Negotiated Testing Agreements for methyl ethyl ketone (MEK) and methyl isobutyl ketone (MIBK). The testing consisted of a battery of five assays to assess the ability of MEK and MIBK to produce mutations in the genes of bacteria and mammalian systems, to change chromosomal morphology and to transform cells in culture. An inhalation 90-day study and an inhalation teratology study were conducted in rats and mice for MIBK. These data were already available on MEK. For MEK, there was no evidence of genetic or transforming activity in any assay, and the Panel concluded that there is no concern over oncogenic or mutagenic activity and that no further mutagenicity or oncogenicity testing is needed. MIBK was clearly negative in three of the five mutagenicity tests and not clearly positive in any of the five tests. These results combined with the results of the 90-day study led the Panel to conclude that no further mutagenicity or oncogenicity testing is needed. In the 90-day study, the only effects noted were a slight increase in liver weight and an increase in the number of hyalin droplets in male rat kidneys. The results of this study do not suggest that MIBK poses an unreasonable risk of chronic health effects. The teratology study confirms that MIBK lacks teratogenic activity and embryo-fetotoxicity at exposure levels that are nontoxic to mothers. Thus, exposure to MIBK under current use conditions should not pose a risk of teratogenic effects. The results of the 90-day and teratology studies taken together indicate that further reproduction effects testing is unnecessary. NAPHTHENATE METAL SOAPS -- The Program Panel received an approval from EPA on its protocol for a dermal absorption study on lead and cobalt naphthenates. EPA, under TSCA Section 4(a), issued a "no-test" decision because the industry group had voluntarily undertaken a dermal absorption study. The Program Panel will expand its scope of activities to Include zinc and copper naphthenates. In its expanded scope, the Panel will interact with EPA's Office of Pesticides in deciding on CMA 012656